The Year of AI
Our December issue takes a pulse check on where the industry stands with artificial intelligence—spotlighting the latest AI-driven approaches in clinical development.
As we near the end of 2024 and reflect on the year that was for clinical research, it would be remiss for us to not acknowledge where we currently stand with artificial intelligence (AI). Its promises are well known by now, from automating patient recruitment to streamlining data operations, and much more. I’m sure 2025 will see AI take an even stronger hold on the industry, but we must be vigilant in maintaining ethical research practices that prioritize our most important stakeholder—patients.
In a video interview with Applied Clinical Trials earlier in 2024, Stephen Pyke, chief clinical data and digital officer, Parexel, said, “…Of course the patients are the most important stakeholder in this whole process. AI is a new technology in its current format. It's building on strong foundations, but there’s a lot that is still new and unknown and we want to make sure that we use it wisely, carefully, responsibly, ethically, and so on.”
Our December issue spotlighting the latest AI-driven approaches in clinical development begins with a feature on synthetic clinical trial data. It highlights a use case on incorporating simulated data, which can potentially change the way trials are designed and executed, and offer a lower level of risk with enhanced efficacy. Next is a piece on the benefits of generative AI (GenAI) in the contract research organization (CRO) space. The article presents concrete examples of how GenAI can help CROs streamline processes involving analytics, databases, and more.
Another feature this month places an emphasis on the use of AI for protocol design and site support. Sponsors can leverage AI by organizing data that provides critical insights into patient and site burden. Rounding out our quartet of December features is a piece, originally published in sister brand Pharmaceutical Executive, that focuses on breaking down traditional siloes in clinical research with the help of AI. Enabling the use of technology allows for more flexibility in trial design elements, which greatly benefits the patient journey. Check out our "In Focus," Q&A, and Closing Thought installments this month as well for AI-related insights.
As we conclude our coverage for 2024, I am excited at what awaits us as an industry in 2025. Thank you for reading.
Mike Hennessy Jr is president and CEO of MJH Life Sciences®
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
The Importance of Real-World Evidence in Medical Research and Drug Development
February 18th 2025The ongoing evolution of real-world evidence from a novel concept to a cornerstone of modern medical research signifies its growing importance and vast potential to improve personalized medicine, overall healthcare outcomes, and eventually democratization of scientific facts by general accessibility.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
